Intercept Pharmaceuticals, Inc.(ICPT)

Description: Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.

---

Keywords: Diabetes Acid Alcohol Hypertension Liver Disease Fibrosis Gastroenterology Diarrhea Steatohepatitis Hepatology Digestive Diseases Cirrhosis Primary Biliary Cholangitis Bile Acid Obeticholic Acid Chronic Liver Disease Chronic Liver Diseases Bile Acid Diarrhea Farnesoid X Receptor Fxr

---

Home Page: www.interceptpharma.com

ICPT Technical Analysis

10 Hudson Yards
New York, NY 10001
United States
Phone: 646 747 1000

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)